AbbVie Retained Earnings (Accumulated Deficit) 2010-2024 | ABBV

AbbVie retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $-3.768B, a 310.62% decline year-over-year.

  • AbbVie retained earnings (accumulated deficit) for 2023 were $-1B, a 120.9% decline from 2022.
  • AbbVie retained earnings (accumulated deficit) for 2022 were $4.784B, a 52.99% increase from 2021.
  • AbbVie retained earnings (accumulated deficit) for 2021 were $3.127B, a 196.4% increase from 2020.

AbbVie Retained Earnings (Accumulated Deficit) 2010-2024 | ABBV

  • AbbVie retained earnings (accumulated deficit) for 2023 were $-1B, a 120.9% decline from 2022.
  • AbbVie retained earnings (accumulated deficit) for 2022 were $4.784B, a 52.99% increase from 2021.
  • AbbVie retained earnings (accumulated deficit) for 2021 were $3.127B, a 196.4% increase from 2020.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$860.1B
Novo Nordisk (NVO)$592.6B
Johnson & Johnson (JNJ)$400B
Merck (MRK)$300.5B
AstraZeneca (AZN)$243.6B
Novartis AG (NVS)$237B
Pfizer (PFE)$168.6B
Sanofi (SNY)$145.6B
Innoviva (INVA)$1.2B